

[Back to Overview \(https://my.ean.org/s/abstracts\)](https://my.ean.org/s/abstracts)**Abstract
A-23-08441**[Abstract FAQs](#)[Withdraw](#)**▼ Information**

Event

[Congress Budapest 2023 \(/s/event/a1M3Y000006n1xLUAA/congress-budapest-2023\)](#)

Type

Poster

Abstract Topic

MS and related disorders

Date Submitted

30/01/2023, 7:18 pm

Stage

Submitted

Status

Pending

▼ Body

Title

Outcomes of COVID-19 in Ofatumumab-treated RMS Patients: Data from the ALITHIOS open label extension study

Introduction

COVID-19 has created challenges in the management of patients with multiple sclerosis (MS). Data collected since the start of the pandemic to 25-Sep-2021 on COVID-19 outcomes in ofatumumab-treated relapsing MS (RMS) patients were previously reported. Here we present updated cumulative COVID-19 outcomes from the ongoing ALITHIOS study up to cut-off: 25-Sep-2022.

Methods

Incidence, seriousness, severity, and outcomes of COVID-19, including cases after initial and booster vaccinations, were analyzed in ofatumumab-treated patients from the ALITHIOS study. Risk factors associated with serious COVID-19 were also evaluated.

Results

Of 1703 patients entered ALITHIOS (mean age at baseline: 39.2 years; females, 69.6%; BMI \geq 30 kg/m², 18%), 648 (38.1%) reported COVID-19 (confirmed, 603; suspected, 45). Most cases were non-serious (598; 92.3%). The majority of cases were mild-to-moderate in severity (94.0%); most patients recovered (96.1%), recovering (0.6%) or recovered with sequelae (1.9%). Five patients had fatal outcome (unvaccinated, 3; fully vaccinated, 2). Post-vaccination COVID-19 cases mainly occurred during the SARS-CoV-2 Omicron wave. Seriousness and severity of COVID-19 decreased in patients following booster vaccination (Table). After adjusting for age, race, vaccination status, EDSS, number of underlying conditions, and time since first dose of ofatumumab, association with higher risk of serious COVID-19 was found in BMI \geq 30 kg/m² vs $<$ 30 kg/m² (HR 1.99) and male vs female (HR 1.86) (Figure).

Conclusion







Most COVID-19 cases in RMS patients receiving ofatumumab in ALITHIOS were non-serious, mild-to-moderate in severity, and most patients recovered. Except for known risk factors for serious COVID-19, such as sex and BMI, no other risk factors have been identified.

Disclosure

The study was supported by Novartis Pharma AG, Switzerland. The detailed author disclosures will be presented in the subsequent presentation.

Author Details

H. Wiendl¹, A. Cross², S. Delgado³, M. Habek⁴, N. Khachanova⁵, B. Ward⁶, B. Cree⁷, N. Totolyan⁸, L. Mancione⁹, R. Sullivan⁹, R. Zielman¹⁰, X. Hu⁹, A. Gupta¹¹, X. Montalbán¹², K. Winthrop¹³; ¹ Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany, ² Washington University School of Medicine, Saint Louis, Missouri, USA, ³ University of Miami Miller School of Medicine, Miami, Florida, USA, ⁴ University Hospital Center Zagreb, University of Zagreb, School of Medicine, Zagreb, Croatia, ⁵ Pirogov Russian National Research Medical University, Moscow, Russia, ⁶ Infectious Diseases Division, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada, ⁷ UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, USA, ⁸ First Saint Petersburg State Medical University, St. Petersburg, Russia, ⁹ Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, ¹⁰ Novartis Pharma B.V., Amsterdam, Netherlands, ¹¹ Novartis Healthcare Private Limited, Hyderabad, India, ¹² Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, ¹³ School of Public Health at Oregon Health & Science University, Portland, Oregon, USA

Attached Files						
Title	Caption	Section	Preview	Download		
 Table_COVID-19 outcome with OMB.png	Table: Summary of COVID-19 ...	Results	Preview 	Download 		
 Figure_COVID-19 outcome with OMB.jpg	Figure: Hazard ratios from Co...	Results	Preview 	Download 